Camp4 Therapeutics reported FY25 GAAP EPS of -$2.65, missing expectations, but ended with a robust $109.5 million cash position. Liquidity was significantly strengthened by private placements, equity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results